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Recent activity by others in heart transplantation makes this review of some
60 years of scientific experiment of timely interest. Present obstacles and future
goals are cited.—Ed.

Homotransplantation of tlie Heart: A Synopsis
Rodman E . Taber, M.D.*

An obituary in the Argentine newspaper. La Nacion (February 5, 1968), recently
recorded the death of Ana Carrel in the province of Cordoba, at the age of 91. Ana
Carrel was the widow of Alexis Carrel — one of the great medical innovators of this
century, particularly in the field of organ transplantation. In 1905, while this unusual
man was working at the University of Chicago, he reported the homotransplantation
of a dog's heart.' He also successfully performed vascular homografts and even
transplanted the head, kidney and hind limb of one animal to another. The recipient
of his canine heart graft lived but two hours. However, this visionary accomplishment
assumes added importance when considered in respect to the period in which it was
performed. The transplant was accomplished in the same year the Wright brothers
were making their epochal flight! Carrel received a Nobel prize for his efforts.
Fifty-five years later, the second Nobel prize to be awarded to medical scientists was
given to Medawar' and Burnet^ for their contribution describing the mechanism of
homograft tolerance and rejection. Their work was made possible, of course, by the
1862 studies of an Austrian monk, Gregor Mendel, who developed the theory of
inheritance by crossing various strains of peas.
Without surveying the previously reported work in the field of experimental heart
homografting, the recent dramatic clinical transplants may appear, at first consideration,
to have a limited scientific background. Actually, large numbers of competent investigators and clinicians have worked toward the goal of replacing the irreparably damaged
human heart with a healthy donor organ.
In 1905, when Carrel performed the first experimental cardiac transplant, he
anastomosed the vessels of a puppy's heart to the cervical vessels of another dog — an
allograft. Arterial blood from the proximal carotid artery of the recipient perfused the
right heart, and blood from the distal carotid artery of the recipient traversed the left
heart ( F i g . l ) .
*Associate Physician, Thoracic Surgery Division
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In 1933, 28 years later, Mann of the Mayo Clinic^ modified this procedure so that
the donor heart coronary arteries were perfused at systemic arterial pressure, and the
heart continued to beat for eight days.

A t this eariy date he recognized that immuno-

logic rejection was the cause of death in his transplants.
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Figure 1
The experimental model used by Carrel in 1905 for the first heart homotransplant. A donor puppy
heart was anastomosed to the cervical vessels of the recipient dog. The ends of the divided recipient
carotid artery and jugular vein were anastomosed to the inferior vena cava, pulmonary artery, aortic
arch and a pulmonary vein of the donor organ.
By permission of P. Hairston and the Journal of Thoracic and Cardivascular Surgery (50:1, 1965).
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Marcus, in 1933,^ further modified the experimental model of Carrel to utilize
the principle of requiring the heart to perform a work load instead of remaining in a
parasitic manner. Survival of the transplants was improved. This investigator also
described transplantation of the heart and lungs of one dog to the abdominal aortic and
vena caval position of another where they formed an auxiliary organ system.'
A Russian, Demichov,' utilized the same transplantation procedure again in 1959
and achieved survival of a dog for 32 days. This feat held the world record for several
years.
Deep hypothermia at 20°C was used by Neptune and Bailey' in 1953 to accomplish
experimental transplantation of donor heart and lungs to the normal intrathoracic or
orthotopic position; however, the animal lived only six hours.
Experimental transplantation of the heart alone into the orthotopic position of the
recipient, that is, replacing the heart as used clinically, should be credited to Goldberg*
who performed it in 1958 but was unable to obtain a surviving dog.
A genuine technical breakthrough occurred in 1960 when Lower and Shumway' of
the Stanford Medical Center at Palo Alto were able to report orthotopic heart transplantation in dogs with survival for up to 21 days. They described an operative method
in which the posterior portions of the atria containing the pulmonary vein orifices and
vena cavas were left intact in the recipient. This procedure greatly simplified the
anastomoses by eliminating the need for individual suturing of the pulmonary veins and
vena cavas (Fig. 2). Barnard'" modified this anastamotic method so as to avoid injury
to the sinus node area at the superior vena caval-right atrial junction, thereby preserving a normal sinus rhythm in the donor organ.
Autotransplantation, a procedure in which the heart of an experimental animal is
completely divided from its connections and resutured in place, has been used for
physiological study of the denervated heart graft and as an exercise in operative technique
for surgeons. Survival of these animals beyond 18 months has been attained by two
groups of investigators." '^ Surprisingly, cardiac output measurements and metabolic
studies in these 18-month survivors revealed all of the physiologic signs of nerve regeneration.'^ Several of the animals had a normal sinus rhythm and there was a physiological response to exercise and pharmacologic stimulation with adrenalin.
Organ Storage
Since it would indeed be uncommon that the death of a satisfactory heart donor
would occur at the proper moment for tranplantation into a patient, there is a need
for storage methods which will allow short-term organ preservation without loss of
transplantability. Satisfactory organ storage becomes even more desirable as means for
tissue typing are developed which require a brief period for matching procedures to be
performed. A variety of storage methods have been suggested and tested experimentally.
As a reference point, experiments by Wuerflein and Shumway''' demonstrated that
leaving the donor heart in a canine cadaver at room temperature for more than 1 to IV2
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hours resulted in sufficient anoxic damage to the myocardium so that only a few of the
hearts could be successfully transplanted. Organ storage techniques and time limits of
the various methods have been reported as follows:
Hypothermia at 4 ° C — 12 hours"
Hypothermia and hyperbaric O2 (2 atmospheres) — 24 hours"
Hypothermia and hyperbaric O2 (8 atmospheres) — 48 hours"
Intermediate host — 24 hours"
Biologic heart-lung storage — 24 hours"
Pump oxygenator perfusion and hypothermia (kidney) — 72 hours"
Other more imaginative ideas have been suggested for organ storage which may
become feasible with continued progress in the area of immunosuppression. It has been
postulated that a baboon colony might be conditioned immunologically to act as an organ
donor farm and the ape family has also been suggested as an intermediate host in which
a human donor heart could be kept functioning and viable until needed. Both of these
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Figure 2
Operative procedure for transplantation of the heart based on the method of Lower and Shumway «
The artial anastomosis is first completed by approximation of the adjacent portions of donor and
recipient tissue with a continuous suture. The posterior walls of the donor heart atria have been
excised and tailored to match the recipient heart remnant.
In order to preserve the sinoatrial node and maintain a normal sinus rhythm in the donor organ the
superior vena caval — right atrial junction area is left intact as advised by Barnard."" Enlargement of
the donor right atrial opening is gained by extending the incision into the atrial appendage. The
procedure is completed by suture anastomosis of the pulmonary artery and ascending aorta.
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proposals require attenuation of the rejection phenomenon beyond that available at this
time. In this area of clinical investigation, the unsuccessful 1964 chimpanzee-to-man
cardiac transplantation at the University of Mississippi by Hardy ^' has almost been forgotten. Another novel approach to organ storage was suggested by recently reported
experimental work indicating that intra-arterial hydrogen peroxide (0.2%) furnished
the same degree of protection against anoxia as that of hyperbaric storage at two
atmospheres pressure of oxygen."
The clinical heart transplants performed in Capetown and Palo Alto have utilized
external cardiac compression or femoral artery to femoral vein perfusion with a pump
oxygenator to preserve the donor organ in the cadaver, while preparations were made
for the transplantation. This application of existing pump oxygenator equipment will
prevent anoxic damage to the tissues at the cost of a reasonable amount of blood trauma
for two to three hours. San Francisco workers have devised a modification of a membrane pump oxygenator system for perfusion storage of organs which extended the
preservation period to 72 hours for renal homografts."
Immunology
Inability to suppress the transplant rejection reaction without serious or fatal side
effects is undoubtedly the greatest barrier to more widespread and successful organ
transplantation. A n indication of the slow progress in this field to date is apparent
when one recalls that with the exceptions of tissue typing and antilymphocyte serum,
the rejection minimizing measures used in the cardiac transplants thus far in 1968 were
essentially the same as those employed by Merrill ^ at the time of his first cadaver
kidney transplant in 1962. Prednisone, and usually cortisone, have been routinely
employed in most treatment protocols, supplemented by one of the nuclear D N A metabolic inhibitors such as 6-mercaptopurine, azathioprine or methotrexate. Whether the
latter drugs actually act specifically in an immunosuppressive manner, or are only antiinflammatory agents, remains to be proven. Whole body irradiation of the recipient —
to suppress immunologic activity in the bone marrow and reticuloendothelial system
— has been largely discarded because of inability to avoid a lethal degree of suppression
in these vital areas. Irradiation of the donor organ to suppress antigenic activity, however, is receiving considerable attention and has been used for human cardiac and renal
transplants. Continued interest is also being maintained in depleting the body of
immune-active lymphocytes and subcellular elements by producing a chronic fistula of
the thoracic duct. To date, there has been no reported application to cardiac transplantation of the principle of chronic local infusion of immunosuppressive agents through
an indwelling intra-arterial cannula in the organ, such as has been applied to renal
homografts. Such a regional approach to immunosuppressive therapy might be
possible in cardiac transplants through use of a small catheter in the aortic root near
the coronary ostia.
There is, of course, no need for immunosuppression in a patient receiving an
isograft, the donor organ coming from a genetically (monozygotic) identical twin, such
as is possible with paired organs. Blood group matching between recipient and donor
has been found helpful in minimizing the rejection reaction in renal transplants and pre261

Taber
sumably would be of value with cardiac grafts. For instance, the second Palo Alto
heart transplant donor was a patient with the universal donor blood group — type O.
Pretransplant tissue typing with various antigens and the detection of cytotoxic antibodies will apparently play an increasingly important role in the matching of donor
organs and recipients. An extensive project has been funded through the National
Institutes of Health to set up regional laboratories for this purpose. Antilymphocyte
serum or globulin is a similarly selective approach to ameliorating the rejection reaction
in distinction to the administration of pharmacologic immunosuppressive agents which
indiscriminately suppress immunologic activity. To make antilymphocyte globulin
( A L G ) , a homologous blood cell or tissue antigen is used to produce a hyperimmune
serum in the horse. The serum may be administered pre- and postoperatively to the
patient for suppressing the activity of antibody forming lymphocytes, possibly without
producing a lymphopenia. Starzl" has used A L G extensively in renal homotransplants
from both related and unrelated donors. His results suggest that it improves renal transplant survival. Unfortunately, as presently carried out, harvesting and purification of the
serum is time-consuming and costly. Interestingly, the second Capetown heart transplant
patient did not receive antilymphocytic serum but tissue typing was employed. When
these types of selective immunosuppression are more highly refined, it will be logical to
direct more attention toward the use of cardiac heterografts — donor organs obtained
from species other than man. That immunologic problem possibly will be more easily
solved with the experience gained in managing homograft rejection.
Pathologic Considerations
The pathologic findings in homograft rejection have been extensively investigated
by Drs. Chiba and Bing'= of Wayne State University. Their studies were made using the
experimental model of cervical homotransplantation of the heart in dogs similar to that
originated by Carrel. They were able to demonstrate to their satisfaction that the homograft rejection reaction is mediated in part through circulating antibodies in the gamma
globulin fraction of the blood and that it involves both cellular and subcellular elements.
They were able to show that the eariiest local tissue alteration, after homotransplantation, was accompanied by increased vascular permeability in the graft as measured by
the injection of radio-iodinated albumin." They postulated that it was mediated through
release of histamine from mast cells in the donor organ. Altered vascular permeability
occurred within one hour of transplantation and preceded perivascular round cell
infiltration which became apparent at three hours. Following this stage, there was
evidence through histological staining techniques of increased RNA content in the perivascular plasma cell infihrate which was thought to be a sign of protein antibody
synthesis. By 19 hours post-transplant, Aschoff-type giant cells appeared in the cellular
infiltrate and within a few days, a vasculonecrotic reaction was evident. Following this,
a granulomatous myocarditis with necrosis appeared, resulting in death of the untreated
transplant in six to eight days. Bing and associates also studied the metabolism of heart
grafts and showed that glucose was utilized with the production of pyruvate and lactic
acid. Their investigation" indicated that hypoxia was not present, as manifested by a
positive redox potential across the transplant (difference between pyruvate and lactate
levels in arterial and coronary sinus blood).
262
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In order to evaluate the propriety of human cardiac transplantation at this time, a
review of the published survival record of experimental homografts is in order. Fiveday survival of untreated combined heart-lung transplants was reported as early as
1961." This was followed shortly by 21-day survival of an untreated orthotopic heart
homograft.' The longest survival of an untreated orthotopic cardiac transplant thus far
reported was 313 days. Kantrowitz and associates," who performed the procedure under
deep hypothermia at 16°C without a pump oxygenator, reported that the animal died of
an obstruction at the atrial suture line, and that the heart failed to show pathological
evidence of rejection. Most of the animals in his series, however, succumbed in the
shorter period of 21 to 57 days. Orthotopic heart transplants treated with methotrexate
(.Imgm/kg every other day) have survived 42 days and Blumenstock," who reported
this work, stated that most of the animals died of drug toxicity rather than myocardial
necrosis. The most encouraging evidence for long-term survival of organ transplants is
that which has tieen obtained with renal homotransplants from related donors, some of
which are now surviving up to five years. Most of these patients continue to receive
intermittent immunosuppressive medication.
The administration of antirejection therapy, according to need rather than on a
daily basis, constitutes a significant recent advance in the field. Shumway" has been
able to maintain orthotopic cardiac homotransplants in the dog for three months to one
year with this type of program. The one-year survival, however, incurred permanent
bone marrow damage due to the immunosuppressive therapy which necessitated frequent
whole blood transfusions.
Periodic biopsy of the kidney transplant has been helpful in directing the administration of antirejection medication on an intermittent or demand basis but this is impractical in heart grafts. With cardiac transplants, both experimental and in the recent
clinical cases, alterations in the EKG have proved to be the most valuable indicator of
the rejection activity level. Shumway has described these findings, the most important
of which consists of a reduction in the "R" wave voltage." Although progression of the
EKG changes reliably predicts death due to necrosing myocarditis within 18 to 24 hours,
most investigators have noted a remarkable preservation of cardiac function until immediately before death. Serum enzyme determinations, such as the lactic acid dehydrogenase (LDH) and serum glutamic oxaloacetic transaminase (SGOT), have been of
little demonstrated value in predicting rejection activity."
Clinical Heart Transplantation
Since the giant step into the era of clinical heart transplantation by Barnard of
Capetown on December 2, 1967, a total of 14 have been carried out up to the time of
this writing (May 20, 1968). With the exception of the infant patient of Kantrowitz's
with tricuspid atresia and one of Cooley's patients with triple valve disease, the indications for transplantation have been progressive and intractable heart failure or other
complications of ischemic coronary artery disease. Now that the longest survivor, 58year-old dentist Phillip Blaiberg of Capetown, is apparently progressing satisfactorily five
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months post-transplant, patients with other forms of heart disease should be considered
as candidates for cardiac replacement. These might include patients with rhabdomyosarcoma of the heart and those with progressive myocardopathies as weU as some
uncommon congenital lesions not amenable to currently employed surgical procedures.
Nonmedical Considerations
There are, of course, myriad unsolved problems in the exciting field of organ transplantation. Even the most skeptical must soon admit, however, that a more pertinent
question than "Was clinical heart transplantation premature?" would be "How
long will it be before the procedure is more widely and successfully practiced?" Some
members of the medical profession claim privately and in die public communications
media that the problems of "What is death?" and "When does it occur in an organ
donor?" are formidable barriers, the solutions of which should involve clergymen,
lawyers, philosophers and administrators, as well as government representatives. Unfortunately, with this approach, the most knowledgeable workers in the field of transplantation — the clinicians — are greatly outnumbered by well-meaning, but pooriy
informed, advisors. Undoubtedly, more accurate criteria to establish the time of irreversible antemortem brain damage in a potenial heart donor — the accepted yardstick
of inevitable death — will be forthcoming, now that the need is apparent. At present, it
would seem appropriate that this determination should be left to the most informed
and experienced, ie, the neurosurgeon. Undoubtedly a degree of objectivity will be
added to this evaluation by requiring that the EEG show an absence of electrical
activity for a specified period.
Medical spokesmen for the National Science Foundation have recentty stated that
human cardiac transplantation is justifiable on an investigational basis. Also, it should
be done by those with a background in appropriate experimental work along with the
availability of necessary ancillary personnel experienced in managing the problems
peculiar to the transplantation field.
In order to estimate the number of potential heart transplantation procedures which
might be required in a medical center, such as the Henry Ford Hospital, the autopsy
records for a one-year period were studied. During 1961, there were 780 autopsies,
and 48 of these deaths occurred in patients who might be considered potential donors.
They involved patients under 50 years of age without clinically significant infection or
heart disease. Twenty-eight of the 48 potential heart transplant donors were patients
with fatal central nervous system or kidney disease. Six were children under five years
of age. Concerning potential recipients, there were 55 autopsies during the year in
patients under 65 years of age in which the cardiac pathology was not a type amenable
to currently practiced surgical procedures, such as valve replacement. Twelve of the 55
potential transplant recipients were under five years of age. It was surprising to note
this approximate balance between potential recipients and donors.
Although investigation in the field of cardiac transplantation has been undertaken
sporadically throughout a 60-year period, the important advances have been forthcoming
264
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in the last seven years. I t seems reasonable to speculate that a continuation of the
present level of progress will shortly place clinical cardiac transplantation on a sound
footing, resulting i n as yet untold benefits f o r patients with otherwise incurable heart
disease.

Addendum:
A review of the clinical heart transplants described in current magazines and the
public press as of August 2, 1963, indicates that a total of 26 human transplants have
been performed by 18 different teams. Seven survivors were recorded with the Capetown
second patient now eight months post-transplant.
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